Haruhide Kimura

Haruhide Kimura

Auto-generated profile, based on publicly available information

Haruhide Kimura

Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
HYHiroshi Yukitake
Hiroshi Yukitake
TFTatsuhiko Fujimoto
Tatsuhiko Fujimoto
TITakashi Ishikawa
Takashi Ishikawa
ASAtsushi Suzuki
Atsushi Suzuki
YSYuji Shimizu
Yuji Shimizu
HKHaruhide Kimura
Haruhide Kimura

5 February 2016 in Neuropsychopharmacology
Verified
Journal Article
Closed access
KSKazunori Suzuki
Kazunori Suzuki
AHAkina Harada
Akina Harada
HSHirobumi Suzuki
Hirobumi Suzuki
MMMaki Miyamoto
Maki Miyamoto
HKHaruhide Kimura
Haruhide Kimura

1 August 2018 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
YSYuu Sako
Yuu Sako
EKEmi Kurimoto
Emi Kurimoto
TMTakao Mandai
Takao Mandai
ASAtsushi Suzuki
Atsushi Suzuki
MTMaiko Tanaka
Maiko Tanaka
HKHaruhide Kimura
Haruhide Kimura

1 March 2015 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
KSKazunori Suzuki
Kazunori Suzuki
AHAkina Harada
Akina Harada
ESEri Shiraishi
Eri Shiraishi
HKHaruhide Kimura
Haruhide Kimura
Phosphodiesterase 10A (PDE10A) is a cAMP/cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. We evaluated the in vivo pharmacological profile of a potent and selective PDE10A inhibitor, TAK-063 (1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)-pyridazin-4(1H)-one). TAK-063 at 0.3 and 1 mg/kg p.o., increased cAMP and cGMP levels in the rodent striatum and upregulated phosphorylation levels of key substrates of cAMP- and cGMP-dependent protein kinases. TAK-063 at 0.3 and 1 mg/kg p.o., strongly suppressed MK-801 [(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine]–induced hyperlocomotion, which is often used as a predictive model for antipsychotic-like activity in rodents. Upregulation of striatal cAMP/cGMP levels and the antipsychotic-like effect of TAK-063 were not attenuated after 15 days of pretreatment with TAK-063 in mice. The potential side effect profile of TAK-063 was assessed in rats using the clinical antipsychotics haloperidol, olanzapine, and aripiprazole as controls. TAK-063 did not affect plasma prolactin or glucose levels at doses up to 3 mg/kg p.o. At 3 mg/kg p.o., TAK-063 elicited a weak cataleptic response compared with haloperidol and olanzapine. Evaluation of pathway-specific markers (substance P mRNA for the direct pathway and enkephalin mRNA for the indirect pathway) revealed that TAK-063 activated both the direct and indirect pathways of MSNs. These findings suggest that TAK-063 represents a promising drug for the treatment of schizophrenia with potential for superior safety and tolerability profiles.

29 October 2022 in Neuropharmacology
Verified
Journal Article
Open access
ASAtsushi Suzuki
Atsushi Suzuki
HHHiroe Hara
Hiroe Hara
HKHaruhide Kimura
Haruhide Kimura
Ketamine exerts rapid and long-lasting antidepressant effects in patients with treatment-resistant depression. However, its clinical use is limited by its undesirable psychotomimetic side effects. Accumulating evidence from preclinical studies has shown that the antidepressant effects of ketamine are dependent on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) activation, which triggers activation of the mechanistic target of rapamycin pathway and brain-derived neurotrophic factor release. Thus, AMPA-R has emerged as a promising new target for novel antidepressants with a rapid onset of action. However, almost all known AMPA-R potentiators carry the risk of a narrow bell-shaped dose-response curve and a poor safety margin against seizures. Our data suggest that agonistic activity is not only related to the risks of bell-shaped dose-response curves and seizures but also to the reduced synaptic transmission and procognitive effects of AMPA-R potentiators. In this review, we describe our original screening approach that led to the discovery of an investigational AMPA-R potentiator with low agonistic activity, TAK-653. We further review the in vitro and in vivo profiles of TAK-653, including its procognitive and antidepressant-like effects, as well as its safety profile, in comparison with known AMPA-R potentiators with agonistic activity and AMPA, an AMPA-R agonist. The low agnostic activity of TAK-653 may overcome limitations of known AMPA-R potentiators. This article is part of the Special Issue on 'Ketamine and its Metabolites'.

1 March 2016 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
ESEri Shiraishi
Eri Shiraishi
KSKazunori Suzuki
Kazunori Suzuki
AHAkina Harada
Akina Harada
NSNoriko Suzuki
Noriko Suzuki
HKHaruhide Kimura
Haruhide Kimura
Cognitive deficits in various domains, including recognition memory, attention, impulsivity, working memory, and executive function, substantially affect functional outcomes in patients with schizophrenia. TAK-063 [1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one] is a potent and selective phosphodiesterase 10A inhibitor that produces antipsychotic-like effects in rodent models of schizophrenia. We evaluated the effects of TAK-063 on multiple cognitive functions associated with schizophrenia using naive and drug-perturbed rodents. TAK-063 at 0.1 and 0.3 mg/kg p.o. improved time-dependent memory decay in object recognition in naïve rats. TAK-063 at 0.1 and 0.3 mg/kg p.o. increased accuracy rate, and TAK-063 at 0.3 mg/kg p.o. reduced impulsivity in a five-choice serial reaction-time task in naive rats. N-methyl-D-aspartate receptor antagonists such as phencyclidine and MK-801 [(5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine] were used to induce working memory deficits relevant to schizophrenia in animals. TAK-063 at 0.3 mg/kg p.o. attenuated both phencyclidine-induced working memory deficits in a Y-maze test in mice and MK-801-induced working memory deficits in an eight-arm radial maze task in rats. An attentional set-shifting task using subchronic phencyclidine-treated rats was used to assess the executive function. TAK-063 at 0.3 mg/kg p.o. reversed cognitive deficits in extra-dimensional shifts. These findings suggest that TAK-063 has a potential to ameliorate deficits in multiple cognitive domains impaired in schizophrenia.